Avidity Biosciences, Inc.

7.97 USD
+0.04 (+0.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avidity Biosciences, Inc. stock is up 36.71% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.